Pergolide effect on cognitive functions in early-mild Parkinson's disease

L. Brusa, P. Tiraboschi, G. Koch, A. Peppe, M. Pierantozzi, S. Ruggieri, P. Stanzione

Research output: Contribution to journalArticle

Abstract

In the present study, we evaluated the effect of pergolide, a mixed D1/D2 agonist, on cognitive function in mild Parkinson's disease (PD). After a two-week wash-out phase, twenty patients with a Hoehn and Yahr score ≤2.5 entered a 16-week, cross-over study in which the order of administration of pergolide or 1-dopa was randomly assigned. Cognitive assessment was performed after the wash-out phase and repeated after eight weeks (before patients were switched to the other drug) and at the end of the study. There were no significant differences in test scores among the three experimental modalities (off-treatment vs. 1-dopa, off-treatment vs. pergolide, pergolide vs. 1-dopa). In another cohort of comparably mild PD patients we had previously demonstrated that pramipexole, a mixed D2/D3 agonist, slightly but significantly worsened verbal fluency in comparison to 1-dopa; moreover, pramipexole impaired short term verbal memory and attentional-executive functions in comparison to both 1-dopa and the off-treatment condition. Taken together, these findings suggest that dopamine agonists may influence cognition in PD according to their pharmacological characteristics. Unlike the D2/D3 agonist pramipexole, pergolide and 1-dopa, both of which stimulate D1- and D2-receptor subtypes, do not appear to impair cognitive function.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalJournal of Neural Transmission
Volume112
Issue number2
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Pergolide
Dihydroxyphenylalanine
Cognition
Parkinson Disease
Dopamine Agonists
Executive Function
Short-Term Memory
Cross-Over Studies
Therapeutics
Pharmacology
Pharmaceutical Preparations

Keywords

  • Cognition
  • Parkinson's disease
  • Pergolide

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pergolide effect on cognitive functions in early-mild Parkinson's disease. / Brusa, L.; Tiraboschi, P.; Koch, G.; Peppe, A.; Pierantozzi, M.; Ruggieri, S.; Stanzione, P.

In: Journal of Neural Transmission, Vol. 112, No. 2, 02.2005, p. 231-237.

Research output: Contribution to journalArticle

Brusa, L. ; Tiraboschi, P. ; Koch, G. ; Peppe, A. ; Pierantozzi, M. ; Ruggieri, S. ; Stanzione, P. / Pergolide effect on cognitive functions in early-mild Parkinson's disease. In: Journal of Neural Transmission. 2005 ; Vol. 112, No. 2. pp. 231-237.
@article{08016da48b1341688192454875a3f8b9,
title = "Pergolide effect on cognitive functions in early-mild Parkinson's disease",
abstract = "In the present study, we evaluated the effect of pergolide, a mixed D1/D2 agonist, on cognitive function in mild Parkinson's disease (PD). After a two-week wash-out phase, twenty patients with a Hoehn and Yahr score ≤2.5 entered a 16-week, cross-over study in which the order of administration of pergolide or 1-dopa was randomly assigned. Cognitive assessment was performed after the wash-out phase and repeated after eight weeks (before patients were switched to the other drug) and at the end of the study. There were no significant differences in test scores among the three experimental modalities (off-treatment vs. 1-dopa, off-treatment vs. pergolide, pergolide vs. 1-dopa). In another cohort of comparably mild PD patients we had previously demonstrated that pramipexole, a mixed D2/D3 agonist, slightly but significantly worsened verbal fluency in comparison to 1-dopa; moreover, pramipexole impaired short term verbal memory and attentional-executive functions in comparison to both 1-dopa and the off-treatment condition. Taken together, these findings suggest that dopamine agonists may influence cognition in PD according to their pharmacological characteristics. Unlike the D2/D3 agonist pramipexole, pergolide and 1-dopa, both of which stimulate D1- and D2-receptor subtypes, do not appear to impair cognitive function.",
keywords = "Cognition, Parkinson's disease, Pergolide",
author = "L. Brusa and P. Tiraboschi and G. Koch and A. Peppe and M. Pierantozzi and S. Ruggieri and P. Stanzione",
year = "2005",
month = "2",
doi = "10.1007/s00702-004-0193-0",
language = "English",
volume = "112",
pages = "231--237",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer-Verlag Wien",
number = "2",

}

TY - JOUR

T1 - Pergolide effect on cognitive functions in early-mild Parkinson's disease

AU - Brusa, L.

AU - Tiraboschi, P.

AU - Koch, G.

AU - Peppe, A.

AU - Pierantozzi, M.

AU - Ruggieri, S.

AU - Stanzione, P.

PY - 2005/2

Y1 - 2005/2

N2 - In the present study, we evaluated the effect of pergolide, a mixed D1/D2 agonist, on cognitive function in mild Parkinson's disease (PD). After a two-week wash-out phase, twenty patients with a Hoehn and Yahr score ≤2.5 entered a 16-week, cross-over study in which the order of administration of pergolide or 1-dopa was randomly assigned. Cognitive assessment was performed after the wash-out phase and repeated after eight weeks (before patients were switched to the other drug) and at the end of the study. There were no significant differences in test scores among the three experimental modalities (off-treatment vs. 1-dopa, off-treatment vs. pergolide, pergolide vs. 1-dopa). In another cohort of comparably mild PD patients we had previously demonstrated that pramipexole, a mixed D2/D3 agonist, slightly but significantly worsened verbal fluency in comparison to 1-dopa; moreover, pramipexole impaired short term verbal memory and attentional-executive functions in comparison to both 1-dopa and the off-treatment condition. Taken together, these findings suggest that dopamine agonists may influence cognition in PD according to their pharmacological characteristics. Unlike the D2/D3 agonist pramipexole, pergolide and 1-dopa, both of which stimulate D1- and D2-receptor subtypes, do not appear to impair cognitive function.

AB - In the present study, we evaluated the effect of pergolide, a mixed D1/D2 agonist, on cognitive function in mild Parkinson's disease (PD). After a two-week wash-out phase, twenty patients with a Hoehn and Yahr score ≤2.5 entered a 16-week, cross-over study in which the order of administration of pergolide or 1-dopa was randomly assigned. Cognitive assessment was performed after the wash-out phase and repeated after eight weeks (before patients were switched to the other drug) and at the end of the study. There were no significant differences in test scores among the three experimental modalities (off-treatment vs. 1-dopa, off-treatment vs. pergolide, pergolide vs. 1-dopa). In another cohort of comparably mild PD patients we had previously demonstrated that pramipexole, a mixed D2/D3 agonist, slightly but significantly worsened verbal fluency in comparison to 1-dopa; moreover, pramipexole impaired short term verbal memory and attentional-executive functions in comparison to both 1-dopa and the off-treatment condition. Taken together, these findings suggest that dopamine agonists may influence cognition in PD according to their pharmacological characteristics. Unlike the D2/D3 agonist pramipexole, pergolide and 1-dopa, both of which stimulate D1- and D2-receptor subtypes, do not appear to impair cognitive function.

KW - Cognition

KW - Parkinson's disease

KW - Pergolide

UR - http://www.scopus.com/inward/record.url?scp=13244259556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13244259556&partnerID=8YFLogxK

U2 - 10.1007/s00702-004-0193-0

DO - 10.1007/s00702-004-0193-0

M3 - Article

C2 - 15365788

AN - SCOPUS:13244259556

VL - 112

SP - 231

EP - 237

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 2

ER -